文献速递治疗药物监测与药物基因组学

黑色素瘤免疫检查点抑制剂的药代动力学与暴露-效应关系综述

Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

该综述总结黑色素瘤免疫检查点抑制剂(抗CTLA4与抗PD1单抗)的药代动力学特征及暴露-效应关系。伊匹木单抗药代动力学呈线性且非时间依赖性,谷浓度与疗效相关;纳武利尤单抗和帕博利珠单抗呈时间依赖性药代动力学,疗效与谷浓度无关,但抗PD1清除率与患者生存相关。解读这些药物的暴露-效应关系较为复杂,尚需进一步研究治疗药物监测的价值。

要点

  • 伊匹木单抗药代动力学呈线性、非时间依赖性,谷浓度与疗效相关。
  • 纳武利尤单抗和帕博利珠单抗呈时间依赖性药代动力学,疗效与谷浓度无关。
  • 抗PD1清除率与黑色素瘤患者生存相关,但暴露-效应关系解读复杂。

核心结论

  • 免疫检查点抑制剂的暴露-效应关系解读复杂,尚需进一步研究治疗药物监测在黑色素瘤治疗中的价值。

研究设计与样本

  • 综述,总结黑色素瘤免疫检查点抑制剂的药代动力学与暴露-效应关系研究。

主要发现

  • 伊匹木单抗药代动力学呈线性且非时间依赖性,谷浓度与疗效相关。
  • 纳武利尤单抗和帕博利珠单抗呈时间依赖性药代动力学,疗效与谷浓度无关。
  • 抗PD1清除率与黑色素瘤患者生存相关。

关键数值与推荐

  • 伊匹木单抗药代动力学呈线性且非时间依赖性,谷浓度与疗效相关。
  • 纳武利尤单抗和帕博利珠单抗呈时间依赖性药代动力学,疗效与谷浓度无关。
  • 抗PD1清除率与黑色素瘤患者生存相关。

临床怎么用

  • 临床应认识免疫检查点抑制剂药代动力学特征差异,关注抗PD1清除率与生存的关联。

局限性

  • 尚需进一步研究评估免疫检查点抑制剂治疗药物监测在黑色素瘤治疗中的价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors are a new class of monoclonal antibodies that amplify T-cell-mediated immune responses against cancer cells. The introduction of these new drugs, first anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and then anti-programmed death-1 (anti-PD1), was a major improvement in the treatment of advanced or metastatic melanoma, a highly immunogenic tumour. The development strategy for immune checkpoint immunotherapies differed from that traditionally used for cytotoxic therapies in oncology. The choices of doses at which to conduct clinical trials, and subsequently the choice of doses at which to use these new therapies, were not based on the identification of a maximum tolerated dose from dose-escalation studies; thus, pharmacokinetic and pharmacokinetic-pharmacodynamic modelling was essential. The studies conducted have shown that the pharmacokinetics of ipilimumab were linear and not time-dependent. In addition, there was a correlation between the trough concentrations of ipilimumab and its therapeutic efficacy. On the contrary, the anti-PD1 immunotherapies nivolumab and pembrolizumab had time-dependent pharmacokinetics. Their therapeutic efficacy was not related to their trough concentration, but there was a correlation between the clearance of anti-PD1 and the survival of melanoma patients. This review highlights the complexity of interpreting the exposure-response relationships of these agents. Further studies are needed to assess the value of therapeutic drug monitoring of immune checkpoint inhibitors in the treatment of melanoma.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Leven C, Padelli M, Carré JL, et al. Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. Clin Pharmacokinet. 2019. PMID: 31183812. doi:10.1007/s40262-019-00789-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。